MOH — authorised 9 May 2023
- Marketing authorisation holder: CHIESI FARMACEUTICI S.P.A
- Status: likely_approved
MOH authorised Elfabrio on 9 May 2023
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. MOH authorised it on 9 May 2023.
CHIESI FARMACEUTICI S.P.A holds the UAE marketing authorisation.